This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Margaret A. Winker, MD
Senior Editor, JAMA

JAMA. 1994;272(24):1897-1898.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—In response to Dr Wolferman and Dr Temianka, JAMA recognizes that pharmaceutical manufacturers conducting studies on drugs they manufacture have a vested interest in demonstrating efficacy of the drug. Conflicts of interest may be obvious, as in this case, or more subtle.¹ Therefore, JAMA requires all authors to sign the financial disclosure statement² and includes all pertinent information in a footnote as part of the article. However, simply because an individual or company has a conflict does not mean they cannot conduct legitimate research. One purpose of editing and peer review is to evaluate reports of studies for possible biases and flaws and select those with the best science. This study met that test. Specific criteria to assess the quality of drug studies in the literature were recently published by Cho and Bero.³

Investigators increasingly must depend on nongovernmental funds to conduct research. We choose . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?